Drug companies have a job to do and so does Health Canada. When the relationship becomes murky, the public are at risk.
Academic rigor, journalistic flair
Articles on Big Pharma
Displaying 1 - 20 of 70 articles
Every year, thousands of medical devices and drugs are recalled in the US. But the decision to recall a flawed product is often left up to the manufacturer.
OxyContin maker Purdue has reportedly been mulling a bankruptcy filling, just as the first of around 2,000 lawsuits against it prepares to go to trial.
Considered in historical context, Purdue's plan to peddle opioid addiction medicines to vulnerable people is not so surprising. Gilded-Age pharmaceutical companies used similar strategies.
Artificially intelligent drug design programs could discover new therapies for conditions that are difficult or prohibitively expensive to cure.
A new study reveals how many patient groups lobby for new drugs to be funded by public plans in Canada -- all while receiving funding from the companies manufacturing the drugs in question.
Clinical guidelines have a big impact on the care you receive and the drugs you're prescribed. But one in five doctors who write these guidelines have undisclosed ties to drug companies.
Evidence shows that opioid manufacturers fund patient advocacy groups in Canada, distorting policies to protect public health.
Developing drugs is typically the domain of large pharmaceutical companies. But here is an example of drug development for a rare pediatric brain cancer that was done in a university setting.
This week's annual Family Medicine Forum is an opportunity for your family doctor -- to cave or resist in the face of Big Pharma sponsorship and marketing.
Biohacking for cures: what you need to know.
Big Pharma in Canada is far behind the curve when it comes to disclosing what payments to health-care professionals are for.
Noted physician and author Atul Gawande was named CEO of a new health care venture aimed at cutting costs and improving care. But the most important man to keep an eye on in this effort isn't Gawande. It's the middleman.
The US is currently short on 182 drugs and medical supplies. The problem isn't new, but it's frustrating health care workers.
The logic behind U.S. president Donald Trump's proposal that Canada and other countries have been “free-riding” off high prices in the United States is bizarre at best.
How a technology born from finance – the blockchain – can help the pharmaceutical industry to carry out clinical trials that protect patients.
The Saint Regis Mohawk tribe has struck a multimillion-dollar deal with Allergan. But the deal may do more harm than good.
Your guide to a public health crisis that's likely to get worse.
How can we fight the opioid epidemic? Redesign the drugs, rethink how we assess patients and mandate prescription monitoring.
Drug prices in Australia are three times higher than in New Zealand. A key reason is the lack of transparency about taxpayer subsidies for Big Pharma and the companies' own finances.
Top contributors
-
Assistant Professor, Bond University
-
Senior Research Fellow, Bioethics, University of Sydney
-
Professor Emeritus of Health Policy and Management, York University, Emergency Physician at University Health Network, Associate Professor of Family and Community Medicine, University of Toronto
-
Assistant Professor, School of Law, University of Canberra
-
Professor of Bioethics & Medicine, Sydney Health Ethics, University of Sydney
-
Ken Harvey is a Friend of The Conversation.
Associate Professor, School of Public Health and Preventive Medicine, Monash University
-
Associate Professor Politics and Policy Studies, Deakin University
-
Postdoctoral Researcher, Sydney Health Ethics, University of Sydney
-
Lecturer in Accounting & Management, Lancaster University
-
Chair professor, University of Sydney
-
Brett Montgomery is a Friend of The Conversation.
Senior Lecturer in General Practice, University of Western Australia
-
Adjunct Professor, Murdoch University
-
Dean, University of Wollongong
-
Professor; Head, School of Clinical Sciences, Queensland University of Technology
-
Research Leader, Critical and Ethical Mental Health research group, Robinson Research Institute, University of Adelaide
